Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra director Thomas Wilder reported an equity award and updated holdings. He acquired 589 shares of common stock via restricted stock units granted at no cost, which vest in four equal installments on March 31, June 30, September 30, and December 31, 2026. The filing also notes 4,506 shares held indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
Penumbra Inc executive Johanna Roberts, EVP, General Counsel & Secretary, reported equity compensation activity in the form of restricted stock units (RSUs) and related tax withholding. On February 13, 2026, she was granted 2,630 RSUs that vest in four equal installments on February 15 of 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, she received another 2,630 RSUs, vesting annually in four equal installments beginning February 15, 2027, also subject to continued service. The footnotes state that if the Closing of the merger agreement among Penumbra, Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs from these grants will fully vest at that Closing, provided she remains in service through that date. In connection with RSU vesting, 482 shares of common stock were disposed of at $339.30 per share to cover tax withholding obligations, a non-open-market, tax-withholding disposition. Following these transactions, she directly owned tens of thousands of Penumbra common shares, with portions subject to vesting.
Penumbra Inc Chief Financial Officer Maggie Yuen reported multiple equity-related transactions in company common stock. On February 13, 2026, she was granted 2,630 restricted stock units (RSUs) under Penumbra’s Amended and Restated 2014 Equity Incentive Plan, scheduled to vest in four equal annual installments starting February 15, 2026, subject to continued service. On February 17, 2026, she received an additional 2,630 RSUs, vesting annually beginning February 15, 2027, also subject to continued service. Any unvested RSUs from these grants will fully vest if the Closing of the merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., as defined in the January 14, 2026 merger agreement, occurs while she remains in service. In connection with RSU vesting, 481 shares of common stock were withheld by Penumbra on February 15, 2026 at $339.30 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Yuen directly owned 20,785 shares of Penumbra common stock.
Penumbra Inc Chief Accounting Officer Lambert Shiu reported multiple equity compensation transactions involving company common stock. On February 13, 2026, he was granted 2,300 restricted stock units (RSUs) at $0 under Penumbra's Amended and Restated 2014 Equity Incentive Plan, with one quarter scheduled to vest on each of February 15, 2026, 2027, 2028 and 2029, subject to continued service. On February 17, 2026, he received an additional 2,300 RSUs at $0, vesting in four equal annual installments beginning February 15, 2027, also subject to continued service.
The filing notes that if the Closing defined in the January 14, 2026 merger agreement with Boston Scientific Corporation occurs, any unvested RSUs from these grants will fully vest at that Closing, provided he remains in service through that date. On February 15, 2026, 412 shares of common stock were disposed of at $339.30 per share to satisfy tax withholding obligations related to RSU vesting, rather than an open-market sale. After these transactions, he directly owned 39,473 shares of Penumbra common stock, a portion of which remains subject to vesting, and an additional 300 shares are held indirectly through his spouse's IRA.
Penumbra Inc President Shruthi Narayan reported equity compensation and related tax share withholding. On February 13, 2026, she received a grant of 2,630 restricted stock units (RSUs) that vest in four equal annual installments on February 15, 2026, 2027, 2028 and 2029, subject to continued service. On February 15, 2026, 705 common shares were withheld at
FMR LLC and Abigail P. Johnson report a 4.7% beneficial stake in Penumbra Inc. common stock. As of the January 30, 2026 event date, they report beneficial ownership of 1,826,862.09 shares, with FMR holding sole voting power over 1,822,618 shares and sole dispositive power over 1,826,862.09 shares.
The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Penumbra. It also notes that one or more other persons may receive dividends or sale proceeds, but no such person holds more than 5% of the class.
FMR LLC has filed Amendment No. 10 to its Schedule 13G reporting a significant ownership stake in Penumbra Inc. As of December 31, 2025, FMR LLC and related entities beneficially owned 5,100,142.02 shares of Penumbra common stock, representing 13.0% of the outstanding class.
FMR LLC reported sole voting power over 5,086,654 shares and sole dispositive power over 5,100,142.02 shares. Abigail P. Johnson is also a reporting person, with sole dispositive power over the same 5,100,142.02 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Penumbra.
Boston Scientific used its Q4 2025 call to highlight strong growth and the pending acquisition of Penumbra. The Cardiovascular segment grew 16% operationally and organically in the quarter and 21% organic for the full year, reflecting strength in fast-growing markets.
As of December 31, 2025, the company reported cash on hand of
Management closed the acquisition of Nalu Medical and announced deals for Valencia Technologies and Penumbra, expanding into urology and neurovascular/mechanical thrombectomy adjacencies. The CEO reaffirmed long-range goals for 10%+ organic revenue growth from 2026–2028, about 150 bps margin expansion, and strong double-digit EPS growth, while cautioning that these are forward-looking statements subject to significant risks.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at
The transaction is designed to expand Boston Scientific’s cardiovascular portfolio and re-establish a strong neurovascular business, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects roughly
Penumbra Inc.'s president, Shruthi Narayan, reported a routine tax‑related share withholding. On January 15, 2026, the issuer withheld 286 shares of common stock at $350.49 per share to cover tax obligations arising from the vesting of restricted stock units granted to her. Following this transaction, Narayan beneficially owns 26,317 shares of Penumbra common stock, held directly. This reflects an administrative adjustment tied to equity compensation rather than an open‑market sale.